Nuvation Bio Inc.

Nuvation Bio Inc. reported a net income of $5.4 million for Q1 2026, a significant improvement from a $53.2 million net loss in the prior year. The company achieved $18.5 million in net product revenues for IBTROZI, with over 200 new patients starting treatment. Nuvation Bio also secured global development and commercialization rights for safusidenib by acquiring the Japan rights from Daiichi Sankyo, and presented updated positive clinical data for IBTROZI at AACR 2026.

Nuvation Bio reported a significant financial turnaround in Q1 2026, achieving a net income of $5.4 million compared to a net loss of $53.2 million in the same period last year. Total revenue dramatically increased to $83.2 million, up from $3.1 million year-over-year, driven by both new product revenue and substantial growth in collaboration and license agreements. The company also generated positive cash flow from operating activities, totaling $5.1 million.